Ulrik Zeuthen Joins Adalyon as CEO

Why It Matters

Zeuthen’s experience in pharma AI and data integration positions Adalyon to deepen its foothold in drug development pipelines, potentially accelerating trial efficiency and attracting larger pharma collaborations.

Summary

Adalyon, the Finland‑Denmark AI‑driven speech‑biomarker startup that supports clinical drug development, announced the appointment of Ulrik Zeuthen as its new chief executive officer. Zeuthen brings a track record of leading digital transformation initiatives in the pharmaceutical sector, with expertise in data integration and artificial intelligence. His hiring signals a strategic push to accelerate the commercialization of Adalyon's platform and expand partnerships with pharma companies. The move follows the company's recent fundraising round that aims to scale its technology across multiple therapeutic areas.